Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival

BACKGROUND: NETTER-1 trial demonstrated high efficacy and low toxicity of four cycles of Peptide Receptor Radionuclide Therapy (PRRT) in patients with metastasized NET. The present study evaluates the outcome of further PRRT cycles in the so called salvage setting in patients after initial response...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:BMC Cancer
Huvudupphovsmän: Rudisile, S., Gosewisch, A., Wenter, V., Unterrainer, M., Böning, G., Gildehaus, F. J., Fendler, W. P., Auernhammer, C. J., Spitzweg, C., Bartenstein, P., Todica, A., Ilhan, H.
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2019
Ämnen:
Research Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6686531/
https://ncbi.nlm.nih.gov/pubmed/31395036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-6000-y
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk